CliffBio
small molecule

ATROPINE SULFATE

ATROPINE SULFATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameATROPINE SULFATE
Active ingredientATROPINE SULFATE
Strength8MG/20ML (0.4MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL
ModalitySmall molecule
FDA approvalJanuary 2018
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.